COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Alector AL001-3

Alector AL001-3 is a phase-3 study for individuals at risk for or with frontotemporal dementia due to mutations in the progranulin gene. This study will provide genetic testing for individuals with a family history who may be eligible to participate. The length of the trial ranges from 48 weeks to 96 depending on the treatment condition. 

MAIN REQUIREMENTS: Age 18-85; known carriers of heterozygous loss-of-function progranulin gene (GRN) mutations.

Studies
Alector AL001-3
​Required Diagnosis
​Diagnosis of FTD and known carriers of heterozygous loss-of-function progranulin gene (GRN) mutations
Age
​18 - 85 (inclusive)
Length
​6 wks (screening) + 48 wks (symptomatic) or 96 wks (pre-symptomatic) of treatment period + 8 wks (safety follow-up).
Lumbar Puncture
​Optional (1 at screening and 2 during the treatment period)
MRI
​Required
​Amyloid PET
​No
Tau PET
​No
Compensation
​Yes
Contact
clinicaltrialsadrc@health.ucsd.edu
For More Information​
Flyer